Investigating Blocks to B Cell Memory in CVID
研究 CVID 中 B 细胞记忆的区块
基本信息
- 批准号:8381520
- 负责人:
- 金额:$ 31.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-15 至
- 项目状态:未结题
- 来源:
- 关键词:Activities of Daily LivingAgonistAllelesAntibodiesAntibody FormationAntigensApoptosisAutoimmune DiseasesAutoimmune ResponsesAutoimmunityB Cell ProliferationB cell differentiationB-Cell DevelopmentB-LymphocytesCalciumCarbohydratesCell Differentiation processCell Surface ReceptorsCell SurvivalCell physiologyChromosome DeletionComplement Factor BComplexCyclophilinsCysteine-Rich DomainDataDefectDeficiency DiseasesDevelopmentEmployee StrikesFunctional disorderGenesGeneticHomeostasisHospitalizationHumanImmuneImmunityImmunoglobulin AImmunoglobulin Class SwitchingImmunoglobulin Switch RecombinationImmunoglobulinsInstructionLeadLigandsLinkLymphomaMediatingMemory B-LymphocyteModelingMolecularMucosal ImmunityMusMutationPathway interactionsPatientsPlasma CellsPlayPneumococcal InfectionsPneumococcal vaccinePolysaccharidesPrevalenceProductionProtein IsoformsReceptors, Antigen, B-CellRelative (related person)RoleSignal TransductionSmith Magenis syndromeSplenomegalySystemT-Independent AntigensT-LymphocyteTALL-1 proteinTLR7 geneTNFSF5 geneTestingbiological systemscell growthlymphoid hyperplasianovelreceptorreceptor functionresponse
项目摘要
PROJECT SUMMARY (See instructions):
Common variable immune deficiency (CVID) is the clinically most important primary antibody deficiency disease due to prevalence, complications, hospitalizations and requirement for lifelong immune globulin therapy. B cells of patients lack the capacity for normal somatic hyper-mutation and isotype switch, secrete immune globulins poorly, and fail to differentiate into plasma cells. The genetic causes of B cell dysfunction in CVID are largely unknown. Heterozygous mutations in the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) gene are found in 8-10%, but also in relatives with normal immune globulin levels showing that these are not the main cause of severe B cell dysfunction. However, CVID subjects with TACI mutation especially in heterozygous form are significantly more likely to develop striking lymphoid hyperplasia and autoimmunity. Using human B cells and transfectants with TACI mutations, we will investigate TACI receptor function in humans, examining if monoallellic or biallelic mutations in TACI accelerate BAFF/BAFF-R mediated B cell growth ahd differentiation. TLR agonists with TACI signals may promote self-reactivity as well as play a role in B cell differentiation in humans, thus we will examine how these may drive B cell proliferation and autoimmunity in CVID, especially when TACI signals are impaired.
As human B cells have two structurally different TACI isoforms we will determine the differences in functional capacities, and explore the controls on the production of these naturally occurring isoforms. A current hypothesis is that mutations in TACI could lead to haploinsufficiency; we will investigate this by examining B cell function in patients with the Smith Magenis syndrome, who are heterozygous for a null TACI allele due to
a chromosomal deletion. In this project we hypothesize that mutations in TACI found in subjects with CVID and their non immune deficient relatives, can be used to explore how the TACI receptor and its ligands, BAFF and APRIL, control B cell growth and differentiation in humans. These data may be of use in understanding this complex receptor system in human autoimmune disease in general.
项目总结(见说明):
普通可变免疫缺陷病(CVID)是临床上最重要的原发性抗体缺乏病,由于患病率,并发症,住院治疗和终身免疫球蛋白治疗的要求。患者的B细胞缺乏正常体细胞超突变和同种型转换的能力,分泌免疫球蛋白差,不能分化为浆细胞。CVID中B细胞功能障碍的遗传原因在很大程度上是未知的。在8- 10%的患者中发现了跨膜激活因子、钙调节因子和亲环素配体相互作用因子(TACI)基因的杂合突变,但在免疫球蛋白水平正常的亲属中也发现了杂合突变,这表明这些不是严重B细胞功能障碍的主要原因。然而,具有TACI突变的CVID受试者,特别是杂合子形式的CVID受试者,更有可能发生显著的淋巴组织增生和自身免疫。使用人B细胞和具有TACI突变的转染子,我们将研究人中的TACI受体功能,检查TACI中的单等位基因或双等位基因突变是否加速BAFF/BAFF-R介导的B细胞生长和分化。TLR激动剂与TACI信号可能会促进自身反应性,以及发挥作用的B细胞分化在人类中,因此,我们将研究如何这些可能会驱动B细胞增殖和自身免疫性CVID,特别是当TACI信号受损。
由于人类B细胞具有两种结构不同的TACI亚型,我们将确定功能能力的差异,并探索对这些天然存在的亚型产生的控制。目前的假设是,TACI突变可能导致单倍不足;我们将通过检查Smith Magenis综合征患者的B细胞功能来研究这一点,这些患者是TACI无效等位基因的杂合子,
染色体缺失在这个项目中,我们假设在CVID受试者及其非免疫缺陷亲属中发现的TACI突变可用于探索TACI受体及其配体BAFF和APRIL如何控制人类B细胞生长和分化。这些数据可能有助于了解这种复杂的受体系统在人类自身免疫性疾病的一般。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLOTTE CUNNINGHAM-RUNDLES其他文献
CHARLOTTE CUNNINGHAM-RUNDLES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLOTTE CUNNINGHAM-RUNDLES', 18)}}的其他基金
2nd North American meeting by CIS devoted to primary immune deficiency.
CIS 第二届北美会议专门讨论原发性免疫缺陷问题。
- 批准号:
8319023 - 财政年份:2012
- 资助金额:
$ 31.94万 - 项目类别:
Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)
协助原发性免疫缺陷疾病调查的资源 (U24)
- 批准号:
9460354 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)
协助原发性免疫缺陷疾病调查的资源 (U24)
- 批准号:
7812766 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)
协助原发性免疫缺陷疾病调查的资源 (U24)
- 批准号:
8244569 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)
协助原发性免疫缺陷疾病调查的资源 (U24)
- 批准号:
8449169 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
CIS First North American Primary Immune Deficiency National Conference
CIS 第一届北美原发性免疫缺陷全国会议
- 批准号:
7910978 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)
协助原发性免疫缺陷疾病调查的资源 (U24)
- 批准号:
9240568 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)
协助原发性免疫缺陷疾病调查的资源 (U24)
- 批准号:
8642134 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)
协助原发性免疫缺陷疾病调查的资源 (U24)
- 批准号:
8054394 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
Resources to Assist Investigations in Primary Immunodeficiency Diseases (U24)
协助原发性免疫缺陷疾病调查的资源 (U24)
- 批准号:
9013449 - 财政年份:2010
- 资助金额:
$ 31.94万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 31.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 31.94万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 31.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)